Radhakrishnan Maha 4

What Happened

• Radhakrishnan Maha, a director of Entrada Therapeutics, was granted a derivative award (an option) for 19,000 shares on June 10, 2026. The reported acquisition price is $0.00 per share (total reported value $0), and this is an award/option grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10; filing date: 2026-06-12 (appears timely; Form 4s are generally due within two business days).
• Amount/price: 19,000 shares @ $0.00 (derivative).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnote: The shares subject to this option vest and become exercisable on the earlier of (i) the one‑year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.
• No indication in the filing that shares were immediately sold or used for tax withholding.

Context

• This was a compensatory derivative grant (an option) that will only become exercisable after vesting per the footnote. Such awards are common for directors and do not represent an immediate market purchase or sale. They do not, by themselves, indicate the director bought or sold stock in the open market.